Finance

Beta
Lists
NOT:ETR
ნოვარტისი
129,92 €
+0,50%
(+0,64) 1D
29 მაი, 17:35:51 GMT+2  ·   EUR
All symbols
SymbolPriceChange% Change
Generating top insights for NOT...
Open
130,50 €
High
130,64 €
Low
129,56 €
Mkt. cap
303,36 მლრ.
Avg. vol.
1,56 ათ.
Volume
2,18 ათ.
52-wk high
144,12 €
52-wk low
96,75 €
No. of employees
75 ათ.
Open
130,50 €
High
130,64 €
Low
129,56 €
Mkt. cap
303,36 მლრ.
Avg. vol.
1,56 ათ.
Volume
2,18 ათ.
52-wk high
144,12 €
52-wk low
96,75 €
No. of employees
75 ათ.
News stories
From sources across the web
Profile
Novartis AG is a Swiss multinational pharmaceutical corporation based in Basel, Switzerland. Novartis is one of the largest pharmaceutical companies in the world and was the eighth largest by revenue in 2024. Novartis manufactures the drugs clozapine, diclofenac, carbamazepine, valsartan, imatinib mesylate, cyclosporine, letrozole, methylphenidate, terbinafine, deferasirox, and others. Novartis was formed in 1996 by the merger of Ciba-Geigy and Sandoz. It was considered the largest corporate merger in history during that time. The pharmaceutical and agrochemical divisions of both companies formed Novartis as an independent entity. The name Novartis was based on the Latin terms, novae artes. After the merger, other Ciba-Geigy and Sandoz businesses were sold, or, like Ciba Specialty Chemicals, spun off as independent companies. The Sandoz brand disappeared for three years, but was revived in 2003 when Novartis consolidated its generic drugs businesses into a single subsidiary and named it Sandoz. Wikipedia
About ნოვარტისი
CEOვასანტ ნარასიმჰანი
Employees75,3 ათ.
Founded29 თებ. 1996
Headquartersბაზელი, ბაზელ-შტადტის კანტონი, შვეიცარია
SectorPharmaceutical industry
Websitenovartis.com
Last report
28 აპრ. 2026
Fiscal period
Q1 2026
EPS / Est. (USD)
1,99 US$ / 2,08 US$
-4,54%miss
Revenue / Est. (USD)
13,52 მლრდ. / 13,48 მლრდ.
+0,33%beat
Fiscal Q1 2026 earnings call
Waiting for the earnings call
At a glance
Insights from the latest news and reports
Previous reportsAll values in USD
Loading Previous Earnings...
Income statement
Revenue
Net income
All values in USD
ივნ. 2025
სექ. 2025
დეკ. 2025
მარ. 2026
Revenue
14,84 მლრდ.
14,36 მლრდ.
13,86 მლრდ.
13,52 მლრდ.
Cost of goods sold
3,32 მლრდ.
3,54 მლრდ.
3,54 მლრდ.
3,44 მლრდ.
Cost of revenue
3,32 მლრდ.
3,54 მლრდ.
3,54 მლრდ.
3,44 მლრდ.
Research and development expenses
2,62 მლრდ.
2,86 მლრდ.
2,84 მლრდ.
2,78 მლრდ.
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
3,44 მლრდ.
3,30 მლრდ.
3,44 მლრდ.
3,14 მლრდ.
Operating expense
6,05 მლრდ.
6,24 მლრდ.
6,46 მლრდ.
5,96 მლრდ.
Total operating expenses
9,37 მლრდ.
9,77 მლრდ.
10,00 მლრდ.
9,40 მლრდ.
Operating income
5,46 მლრდ.
4,58 მლრდ.
3,86 მლრდ.
4,12 მლრდ.
Other non operating income
-13,00 მლნ.
-7,00 მლნ.
-130,00 მლნ.
4,00 მლნ.
EBT including unusual items
4,53 მლრდ.
4,20 მლრდ.
3,22 მლრდ.
3,84 მლრდ.
EBT excluding unusual items
5,16 მლრდ.
4,29 მლრდ.
3,49 მლრდ.
3,78 მლრდ.
Income tax expense
507,00 მლნ.
266,00 მლნ.
814,00 მლნ.
683,00 მლნ.
Effective tax rate
11,19%
6,34%
25,30%
17,79%
Other operating expenses
-4,00 მლნ.
70,00 მლნ.
190,00 მლნ.
42,00 მლნ.
Net income
4,04 მლრდ.
3,93 მლრდ.
2,41 მლრდ.
3,16 მლრდ.
Net profit margin
27,24%
27,36%
17,38%
23,34%
Earnings per share
2,42
2,25
2,03
1,99
Interest and investment income
-
-
373,00 მლნ.
-
Interest expense
-289,00 მლნ.
-281,00 მლნ.
-304,00 მლნ.
-343,00 მლნ.
Net interest expenses
-289,00 მლნ.
-281,00 მლნ.
69,00 მლნ.
-343,00 მლნ.
Depreciation and amortization charges
-
-
-
-
EBITDA
6,56 მლრდ.
5,78 მლრდ.
4,96 მლრდ.
5,24 მლრდ.
Gain or loss from assets sale
-67,00 მლნ.
81,00 მლნ.
80,00 მლნ.
-159,00 მლნ.
AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer

Research

AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer